TGFβ signaling is believed to significantly contributing as a major driver of the pro-fibrotic phenotype of SSc fibroblasts and anti-TGFβ treatments are being tested in clinical trials with promising results5, 6. The gene discussed is TGFB1; the disease is systemic sclerosis.